The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
EAHP Policy Call 7th March 2017
1) EMVO
To discuss:
– EMVO meeting 3 April
– Reply to Commission – see correspondence HERE
2) HTA Network
– Status update
– Discuss vote
the other organisations have send the following nominations:
European Society of Cardiology (ESC)
Pharmaceutical Group of the European Union (PGEU)
European Union of General Practitioners (UEMO)
European Public Health Association (EUPHA)
Find EAHPs nomination HERE
3) Congress in Cannes
– Members Meeting (please find the draft agenda HERE)
Preparation that is needed
Discussion of last agenda point “other emerging matter” – AMR consultation, biosimilars policy statement
– Individual Meetings
If ok with you, Tony would like to attend your individual meetings
4) Consultations
Commission: AMR – Status update
EMA: Revision of Concept paper on the need for revision of note for guidance on quality of water for pharmaceutical use (H+V) – find more information HERE
To discuss if EAHP should be involved
5) Misc
CTF – current status of the consultation
Pharm Q – Conference Helsinki
Medicines for Europe – multi-stakeholder platform on biosimilar medicines: proposal to join the platform; see correspondence HERE